Mutagen sensitivity and risk of second cancer in younger adults with head and neck squamous cell cancer: 15-year results

Purpose To evaluate the mutagen sensitivity phenotype on the risk of second primary cancer (SPC) in patients with head and neck squamous cell carcinoma (HNSCC), and to estimate the long-term rate of SPC and the outcome with SPC. Methods A survey was made regarding SPC among 124 younger (≤ 50 years)...

Full description

Saved in:
Bibliographic Details
Published in:Strahlentherapie und Onkologie 2022-09, Vol.198 (9), p.820-827
Main Authors: Bukovszky, B., Fodor, J., Székely, G., Kocsis, S. Zs, Oberna, F., Major, T., Takácsi-Nagy, Z., Polgár, C., Jurányi, Z.
Format: Article
Language:English
Subjects:
Adults
Alcohol
Biomarkers
Cancer
Cancer therapies
Cell cycle
Chemotherapy
Chromosomes
Head & neck cancer
Lymphocytes
Medical prognosis
Medicine
Medicine & Public Health
Oncology
Original
Original Article
Radiotherapy
Risk analysis
Sensitivity analysis
Smoking
Surgery
Survival
Tumors
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To evaluate the mutagen sensitivity phenotype on the risk of second primary cancer (SPC) in patients with head and neck squamous cell carcinoma (HNSCC), and to estimate the long-term rate of SPC and the outcome with SPC. Methods A survey was made regarding SPC among 124 younger (≤ 50 years) adults with HNSCC who were enrolled in a pretreatment mutagen sensitivity investigation during 1996–2006. Mutagen sensitivity was assessed by exposing lymphocytes to bleomycin in vitro and quantifying the bleomycin-induced chromatid breaks per cell (b/c). Patients were classified as hypersensitive (> 1 b/c) or not hypersensitive (≤ 1 b/c). Results Mean follow-up time for all patients was 68 months (range: 5–288 months), and the 15-year cancer-specific survival was 15%. Twenty patients (16%) developed a SPC (15-year estimated rate: 41%), and half of them was hypersensitive. The crude rate of SPC for hypersensitive ( n  = 65) or not hypersensitive ( n  = 59) patients were 15 and 17%, respectively ( p  = 0.4272). The 15-year estimated rate of SPC for hypersensitive and not hypersensitive patients was 36 and 48%, respectively ( p  = 0.3743). Gender, UICC stages, anatomical sites of index cancer did not prove to be a significant risk factor for SPC. Forty-five percent of SPC developed after the 10-year follow-up. The 3‑year cancer-specific survival was 23% with SPC. Conclusion According to our findings, mutagen hypersensitivity was not associated with an increased SPC risk in HNSCC patients. Patients are at a lifelong risk of developing a SPC. Survival with SPC is very poor.
ISSN:0179-7158
1439-099X
DOI:10.1007/s00066-022-01917-2